

RANBAXY



Ranbaxy Laboratories Limited

FINANCIAL RESULTS:

- **April - June, 2010 (Q2)**
- **YTD June 30, 2010 (H1)**

Safe Harbor

RANBAXY

2

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute “forward-looking statements”. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

RANBAXY



Ranbaxy Laboratories Limited

FINANCIAL RESULTS:

- April - June, 2010 (Q2)
- YTD June 30, 2010 (H1)

ATUL SOBTI
CEO & MD

12 Aug 2010

Investors Call

RANBAXY



Ranbaxy Laboratories Limited

FINANCIAL RESULTS:

- April - June, 2010 (Q2)
- YTD June 30, 2010 (H1)

OMESH SETHI

President & CFO

12 Aug 2010


Investors Call

Sales Performance


RANBAXY

5

**Consolidated Revenues
Q2 2010**



**Consolidated Revenues
H1 2010**




- Higher revenues from FTFs in the USA
- Broad based overall growth

Sales growth % are calculated at constant forex over Q2'09/H1'09, unless mentioned otherwise

Q2 2010: Sales by Geography/ Segment

RANBAXY

6




Most geographies / business segments grew during the Quarter

Sales growth % are calculated at constant forex over Q2'09/H1'09, unless mentioned otherwise

H1 2010: Sales by Geography/ Segment


RANBAXY

7




H1 continues the trend of consistent broad based growth

Sales growth % are calculated at constant forex over Q2'09/H1'09, unless mentioned otherwise



□ At its peak, Valacyclovir captured 74% market share in the USA

□ New products launched in the US market include Oxycodone CR and Calcitriol




- Retail (non-tender) business in India grew 11%; Groundwork for project Viraat completed; aimed to capitalize on the opportunities in the home market
- Ranbaxy enjoys 4.8% market share in the Indian Pharma Market (IMS MAT May 10)
- Consumer Healthcare business grew 24% on YTD basis
- CHC ranked No. 1 in its represented market: market share increased for all key brands viz., Revital, Volini, Chericof

Sales growth % are calculated at constant forex over Q2'09/H1'09, unless mentioned otherwise

Europe


RANBAXY

10




- Growth momentum continued during the Quarter, led by Romania
- Most large markets grew including Germany, France and the UK
- Lower cost base helped achieve operational efficiencies


Sales growth % are calculated at constant forex over Q2'09/H1'09, unless mentioned otherwise




- Trend of robust growth continued for the second consecutive quarter
- Restructuring and rationalisation of front end helped counter adverse market conditions
- Ranbaxy continues to be the largest company in generic+OTC segment



- Robust growth of 33% during the Quarter and 29% on YTD basis
- In Russia, Ranbaxy is ranked number 1 in its represented market




- De-growth largely due to change of business model in China, Japan and Vietnam
- On the same base, sales grew 15% for the Quarter



- Africa grew 6% during the Quarter and 16% on YTD basis
- Ranbaxy is ranked 6th South Africa and grew 28%, surpassing generic market growth of 16% (IMS MAT May 10)

Latin America



- Sales grew 4% during the Quarter and 19% on YTD basis

Sales growth % are calculated at constant forex over Q2'09/H1'09, unless mentioned otherwise

Financials Q2 2010 & H1 2010 – USD

RANBAXY

16

Q2 09	Q2 10	Particulars in INR Mn	H1 09	H1 10
368	458	Gross Sales	682	999
1	1	Less : Excise duty	1	2
367	457	Net sales	680	998
18	11	Other operating income	22	72
385	468	Total Operating Income	702	1,070
182	168	Total Consumption	324	331
79	82	Employee cost	149	165
113	127	Other Operating expenses	227	260
374	377	Total expenditure	700	756
11	90	EBITDA	2	313
3%	20%	EBITDA (%)	0%	31%
13	15	Depreciation and amortization	26	37
4	26	Interest and other income	8	20
39	(25)	Foreign exchange gain/ (loss) on loans	13	3
41	76	Profit/(loss) from ordinary activities before tax	(3)	299
		Exceptional Items		
-	47	Profit on disposal of long-term investments		47
176	(51)	Forex (loss)/gain on foreign currency option derivatives	(16)	33
217	72	Profit/(loss) after exceptional items before tax	(18)	380
139	72	Net profit/ (loss) from ordinary activities after tax	(14)	282
38%	16%	PAT (%)	-	28%

Operational Result (excluding Forex and Exceptional Items) Q2 2010

RANBAXY

17

Act Q2 09	Act H1 09	Particulars \$ Mn	Act Q2 10	Act H1 10
368	682	Sales	458	999
217	(18)	EBT	72	380
(39)	(13)	Forex (Gain) / Loss on FC Borrowings	25	(3)
(176)	16	Total Impact of Forex (Gain)/Loss	51	(33)
-		Sale of Assets/Investments	(47)	(47)
2	(16)	Operational EBT without Forex/Except Items	101	296
0.6%	-	% to Sales	22.1%	29.7%

Financials Q2 10 & H1 10 – INR

RANBAXY

18

Q2 09	Q2 10	Particulars in INR Mn	H1 09	H1 10
17,953	21,029	Gross Sales	33,537	45,931
34	41	Less : Excise duty	70	76
17,919	20,988	Net sales	33,467	45,855
873	517	Other operating income	1,096	3,320
18,792	21,505	Total Operating Income	34,563	49,175
8,878	7,723	Total Consumption	15,926	15,235
3,858	3,752	Employee cost	7,337	7,564
5,487	5,861	Other Operating expenses	11,194	11,967
18,224	17,336	Total expenditure	34,457	34,766
568	4,168	EBITDA	106	14,410
3%	20%	EBITDA (%)	0%	31%
644	695	Depreciation and amortization	1,283	1,700
203	1162	Interest and other income	414	911
1,908	(1,158)	Foreign exchange gain/ (loss) on loans	635	139
2,035	3,477	Profit/(loss) from ordinary activities before tax	(128)	13,760
		Exceptional Items		
-	2,178	Profit on disposal of long-term investments	-	2,178
8,784	(2,337)	Forex (loss)/gain on foreign currency option derivatives	(764)	1,535
10,819	3,318	Profit/(loss) after exceptional items before tax	(892)	17,473
6,931	3,320	Net profit/ (loss) from ordinary activities after tax	(679)	12,951
38.6%	15.8%	PAT (%)	--	28.2%